Xeris' Acquisition of Strongbridge and Merger under Holding Co

Back in July Xeris Pharmaceuticals, Inc. (XERS) released the definitive proxy statement for the acquisition of Strongbridge Biopharma plc (SBBP). (https://sec.report/Document/0001193125-21-229354/).

Xeris common stocks will also be cancelled and shares of Xeris Biopharma Holdings, Inc. will be issued 1:1

Immediately following and conditioned on the concurrent consummation of the Acquisition, MergerSub, a Delaware corporation and wholly owned subsidiary of HoldCo, will merge with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the “Merger”, and together with the Acquisition, the “Transaction”). At the effective time of the Merger, all existing shares of Xeris common stock (“Xeris common stock”) will be cancelled and will automatically be converted into the right to receive HoldCo common stock on a one-for-one basis.

*“HoldCo” = Xeris Biopharma Holdings, Inc.

Do I have to do anything (sell before, rebuy after) or can T212 facilitate this change to the Xeris common stocks? @Team212

Hey, :wave:

The proposed deal is set to close in Q4. We’ll update shareholders accordingly once there is any news.